• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Therapeutic Response and Disease Progression

Opinion
Video

An expert on idiopathic pulmonary fibrosis describes the therapeutic response of standard-of-care treatments and how multidisciplinary care can be optimized when treating patients.

Video content above is prompted by the following:

  1. How can multidisciplinary care be optimized when treating patients with IPF?
  2. Describe the therapeutic response and disease progression of patients taking standard of care therapies (pharmacologic and non-pharmacologic).
Related Videos
5 experts in this video
Antonio Urbina, MD
4 experts are featured in this series.
4 Experts are featured in this series
4 Experts are featured in this series
4 experts are featured in this series.
4 Experts are featured in this series
4 Experts are featured in this series
Related Content
Lung cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com

Olomorasib Showed Promising Antitumor Activity in NSCLC

December 2nd 2025
Article

The combination of olomorasib and pembrolizumab to treat KRAS G12C-mutant advanced NSCLC showed promising antitumor activity.

Read More

Managed Care Cast Square thumbnail

Managed Care Cast Presents: New Evidence and Economic Considerations in IPF Care

November 25th 2025
Podcast

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

Listen

FDA icon on screen surrounded by medical icons | Image credit: wladimir1804 - stock.adobe.com

Sonrotoclax Receives FDA Priority Review for R/R Mantle Cell Lymphoma

December 1st 2025
Article

FDA has granted sonrotoclax priority review for relapsed mantle cell lymphoma, showcasing promising trial results.

Read More

Inside the Discovery That Changed CML Treatment Forever: Jorge Cortes, MD

Inside the Discovery That Changed CML Treatment Forever: Jorge Cortes, MD

November 11th 2025
Podcast

Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival.

Listen

The significant differences the investigators uncovered between real-world nintedanib usage and clinical trials suggest that more studies are warranted. | Image credit: mi_viri - stock.adobe.com

Real-World Usage of Nintedanib for PPF Differs From Trial Settings

December 1st 2025
Article

New research shows patients commonly take lower doses of nintedanib, and the majority are also taking immunomodulatory drugs.

Read More

Rendering of AML blood cells | Image credit: LASZLO - stock.adobe.com

NPM1 MRD Status Is a Dominant Predictor of AML Relapse After AlloHCT

November 30th 2025
Article

Pretransplant NPM1 MRD testing significantly predicts relapse risk in acute myeloid leukemia.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.